FOXP3 and colitis: - Increase of FOXP3+ cell numbers and percentages and decreased colitis development in mice (73). - Improved cardiac allograft survival in mice, with increased percentage of FOXP3+ cells and increased suppressive capacity of these cells. However, different effects with different dosages (105). - Reduced incidence of graft versus host disease in allogenic hematopoietic stem cell transplantation patients in a phase I/II clinical trial. Accompanied by reduced pro-inflammatory cytokines and increased Treg cell numbers and suppressive capacity (106, 107).